Predict Antidepressant Responsiveness Using Pharmacogenomics
NCT ID: NCT01228357
Last Updated: 2015-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1000 participants
INTERVENTIONAL
2003-02-28
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Second hypothesis is that patients with the associated genetic variation suffer longer from the associated symptom than the patients without the associated genetic variation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non-SSRI treated group
non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
non-SSRI treated group
Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
SSRI treated group
SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline
SSRI treated group
Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SSRI treated group
Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
non-SSRI treated group
Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians
Exclusion Criteria
* potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
19 Years
89 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doh Kwan Kim
M.D., Ph.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Doh Kwan Kim, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Kangnam, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Doh Kwan Kim, MD.PhD
Role: primary
Woojae Myung, MD.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2003-08-07
Identifier Type: -
Identifier Source: org_study_id